Quicking Biotech Co., Ltd. has established itself as a premier manufacturer of high-quality rapid diagnostic tests, with a special emphasis on COVID-19 antigen rapid test kits that deliver reliable results in just 15 minutes. As a company operating under stringent ISO 13485 quality management systems, Quicking Biotech brings decades of experience in the in vitro diagnostics industry to every product it launches. The company’s core mission revolves around making accurate health screening accessible to individuals, families, and organizations worldwide through user-friendly self-test solutions. Whether you need a rapid antigen test for COVID at home or a point-of-care diagnostic tool for a clinic, Quicking’s product line is designed to meet those needs with precision and simplicity. By combining advanced manufacturing processes with rigorous quality control, Quicking ensures that every test kit performs consistently across different batches. The company’s dedication to innovation is reflected in its continuous investment in research and development, which has led to the creation of testing solutions that rival laboratory-grade equipment in accuracy. Furthermore, Quicking Biotech’s global distribution network means that customers in virtually any region can access these essential health tools without delay. With a strong track record in food safety and veterinary diagnostics, the company has successfully translated its expertise into human health applications, particularly in the fight against COVID-19. This background gives healthcare professionals and end-users confidence in the reliability of Quicking rapid tests for a wide range of scenarios. For those seeking more information about the company’s full product range, theProducts page offers an extensive catalog of diagnostic solutions tailored to various needs.

Quicking Biotech was founded in 2006 and has since grown into a recognized leader in rapid detection technologies, serving clients in over 100 countries. The company’s state-of-the-art research facilities and manufacturing plants are located in Shanghai, where every stage of production is monitored to meet international quality standards. One of the standout achievements of Quicking is its ability to scale production rapidly during public health emergencies, ensuring that testing supplies remain available even during periods of high demand. The company’s portfolio includes not only COVID-19 tests but also a variety of other diagnostic tools, such as the rapid strep test, influenza test, monospot test, and RPR test, among others. This breadth of expertise demonstrates Quicking’s deep understanding of infectious disease detection and its commitment to addressing multiple health challenges simultaneously. By maintaining close relationships with regulatory bodies, the company has secured necessary approvals for its products in numerous markets, including CE marking and WHO prequalification for select items. Customers who choose Quicking are not just buying a test kit; they are partnering with an organization that prioritizes scientific accuracy, user safety, and public health impact. To learn more about the company’s history and mission, theAbout Us page provides a comprehensive overview of its achievements and values.

When evaluating any diagnostic tool, accuracy is the single most important criterion, and Quicking rapid tests deliver exceptional performance backed by clinical data. In multiple independent studies, the Quicking COVID-19 antigen rapid test has demonstrated greater than 98% specificity, meaning it produces very few false positive results, along with high sensitivity in symptomatic individuals during the first week of illness. This level of accuracy is comparable to RT-PCR laboratory tests, making the kit a trustworthy option for both screening and diagnostic purposes. The tests are designed to detect the nucleocapsid protein of the SARS-CoV-2 virus, which is present at high concentrations in nasal swab samples during the acute phase of infection. Because the test targets a stable viral protein rather than genetic material, it remains effective even as new variants emerge, reducing the risk of false negatives due to viral mutations. Each production lot undergoes thorough validation against reference panels to ensure consistent performance, and the manufacturing process is fully compliant with ISO 13485 standards. For healthcare providers who rely on multiple diagnostic tools, Quicking also offers complementary products like the rapid strep test for group A streptococcus and the influenza test for seasonal flu, both of which follow the same rigorous quality protocols. The company’s emphasis on accuracy extends beyond COVID-19, as its RPR test for syphilis screening and monospot test for infectious mononucleosis are also trusted in clinical settings around the world. This comprehensive approach to quality assurance means that whether a patient is using a Quicking test at home or in a clinic, the results can be relied upon for informed decision-making. For the latest updates on product validations and regulatory approvals, theNews page regularly publishes company announcements and scientific findings.

The high sensitivity of Quicking rapid tests is particularly valuable for identifying individuals with elevated viral loads, who are most likely to transmit the virus to others. By catching these cases quickly, users can isolate themselves and prevent further spread within their households, schools, or workplaces. Clinical studies have shown that the test performs best when used within the first five to seven days of symptom onset, achieving sensitivity rates above 90% in symptomatic patients. For asymptomatic individuals, the test still provides useful information, though sensitivity may be lower due to reduced viral shedding, and repeat testing over several days is recommended in such cases. Quicking also publishes detailed instructions for proper sample collection, as correct swabbing technique directly affects test accuracy. Each kit includes a step-by-step illustrated guide that minimizes user error, and customer support is available for those who need clarification. The company’s investment in quality control is evident in the traceability of every component, from the nitrocellulose membrane to the buffer solution, all of which are sourced from approved suppliers. This meticulous attention to detail ensures that the test strips deliver clear, easy-to-read results without ambiguities. Healthcare professionals appreciate the consistency of Quicking products, as they can confidently incorporate them into diagnostic algorithms alongside other laboratory methods. For businesses and institutions that need to validate their testing protocols, the company provides technical documentation and performance reports upon request.

One of the defining strengths of Quicking rapid tests is their exceptional ease of use, which allows individuals of all ages to perform testing without any special training or medical background. Each kit contains a pre-filled buffer tube, a sterile nasal swab, a test cassette, and a clearly written instruction leaflet with pictorial diagrams that guide the user step by step. The entire process from sample collection to result interpretation takes approximately 15 minutes, enabling quick decision-making whether at home, in a school clinic, or at a workplace health station. The test cassette features a simple lateral flow design with a control line and a test line, so the outcome is visually obvious: one line means negative, two lines means positive, and no control line means the test is invalid. To further enhance user confidence, Quicking offers optional digital support through a companion mobile application that can read and interpret test results automatically. This app also allows users to store their testing history, share results with healthcare providers via telemedicine platforms, and receive reminders for repeat testing when necessary. Such digital integration is especially useful for employers managing return-to-work programs and for travelers who need to document negative results for border crossing. The company’s focus on accessibility is reflected in the ergonomic design of the swab, which is soft-tipped and sized appropriately for both adults and children. Additionally, the buffer solution is formulated to be non-hazardous and stable at room temperature, so kits can be stored easily without special refrigeration. For those who want to explore the full ecosystem of Quicking diagnostic solutions, theHome page provides an overview of the company’s product families and digital tools.

Clear communication is at the heart of Quicking’s user experience, and the company has invested heavily in making its instructions accessible to diverse populations. The illustrated guides use universally understood symbols and minimal text, reducing language barriers and making the kit suitable for multilingual settings. For individuals who prefer video guidance, Quicking provides online tutorials that demonstrate the testing procedure in real time, covering common mistakes such as insufficient swabbing or improper buffer use. This educational content is freely available on the company website and is regularly updated to reflect best practices. The test kit itself is compact and lightweight, making it easy to carry in a bag or keep in a medicine cabinet for emergency use. Each component is individually sealed to maintain sterility, and the packaging is designed to be opened without tools or excessive force. Quicking also offers bulk packaging options for schools, businesses, and government agencies, with custom labeling available for partner organizations. The digital app feature supports multiple languages and can generate QR-code-based test reports that are accepted by many airlines and border authorities. For elderly users or those with limited tech experience, the paper instructions remain the primary resource and have been tested in focus groups to ensure clarity. Customer service representatives are available via email and phone to answer questions about test interpretation or troubleshooting, further reducing barriers to effective self-testing. This holistic approach to usability ensures that Quicking rapid tests empower individuals to take control of their health without unnecessary frustration or confusion.

Quicking Biotech differentiates itself from other rapid test manufacturers through a combination of cost-effectiveness, speed, and reliable viral load detection that gives users actionable information in minutes. While many competing products offer similar turnaround times, Quicking’s pricing strategy ensures that high-quality testing remains affordable for large-scale screening programs without sacrificing accuracy or safety. The company’s vertical integration — from raw material sourcing to final assembly — allows it to control costs while maintaining strict quality standards, a benefit that is passed directly to customers. In head-to-head comparisons, Quicking tests have shown equivalent or superior sensitivity to leading brands, particularly in the detection of highly contagious individuals with elevated viral loads. This capability is critical for outbreak control because it identifies the people most likely to spread the virus, enabling targeted isolation and reducing community transmission. Another key advantage is the breadth of Quicking’s diagnostic portfolio, which includes not only COVID-19 tests but also the rapid strep test, influenza test, monospot test, and RPR test, allowing healthcare providers to source multiple tests from a single trusted supplier. This consolidation simplifies procurement, reduces administrative overhead, and ensures consistent quality across different testing programs. Furthermore, Quicking’s manufacturing capacity is among the largest in the industry, meaning the company can fulfill bulk orders quickly even during periods of global supply chain disruption. For organizations that need to scale testing rapidly, such as school districts or corporate campuses, this reliability is a significant operational advantage. The company’s dedication to continuous improvement is evident in its active R&D pipeline, which explores next-generation test formats with even faster results and multiplex detection capabilities. To discuss partnership opportunities or bulk purchasing, theContact UsThis page provides direct access to the Quicking sales team.

Competitor products often require users to wait 20 to 30 minutes for results, whereas Quicking tests consistently deliver clear outcomes in just 15 minutes, enabling faster isolation and treatment decisions. This time savings is especially valuable in emergency settings, such as hospital triage or workplace outbreak response, where every minute counts. Additionally, Quicking tests are designed with a high cutoff threshold for positivity, which reduces the likelihood of detecting residual viral fragments that are not associated with active infection — a common issue with some PCR-based methods. This means that a positive Quicking test is a strong indicator of current infectiousness, allowing clinicians to make confident decisions about patient management. The test’s ability to detect the virus across multiple variants, including Delta and Omicron sublineages, has been verified through ongoing surveillance studies, giving users peace of mind that the test remains relevant as the virus evolves. Quicking also provides detailed batch-level performance data to customers, a level of transparency that many larger competitors do not offer. For companies that require regulatory documentation for compliance purposes, Quicking supplies certificates of analysis and CE declarations of conformity with every shipment. The company’s customer support team is trained to assist with technical questions, product selection, and even assay validation studies for institutional clients. This combination of speed, accuracy, affordability, and transparency makes Quicking a compelling choice for anyone seeking reliable COVID-19 self-testing solutions. By choosing Quicking, organizations invest in a partner that understands the real-world challenges of pandemic management and is committed to delivering practical, science-based solutions.

Quicking rapid tests are versatile tools that serve a wide array of applications, from routine home screening to organized public health surveillance and international travel compliance. In home settings, families can use the kits to test members who develop symptoms before deciding whether to visit a doctor or isolate, reducing the burden on healthcare systems. Schools have adopted Quicking tests for weekly screening programs that identify asymptomatic cases early, allowing students to remain in classrooms with minimal disruption when negative results are confirmed. Workplaces, particularly those in essential industries such as manufacturing, hospitality, and logistics, rely on Quicking tests to implement return-to-work policies that keep employees safe and operations running smoothly. The test’s 15-minute turnaround makes it ideal for shift-based testing at entrances, where workers can be screened before entering a facility without creating long queues. Public health authorities have also integrated Quicking kits into community testing campaigns, distributing them through pharmacies, community centers, and mobile testing units to reach underserved populations. For travelers, many airlines and border agencies accept Quicking’s digital test reports as proof of negative status, streamlining the check-in process and reducing the need for costly PCR tests at airports. Beyond COVID-19, Quicking’s portfolio of diagnostics — including the rapid strep test, influenza test, RPR test, and monospot test — supports clinics in differentiating between respiratory and systemic infections, improving treatment accuracy. This broad applicability means that a single order from Quicking can equip a clinic or hospital with multiple testing capabilities, simplifying inventory management and training. The company’s experience in veterinary and food safety diagnostics also informs its human health products, ensuring that the same rigor applies across all sectors.

In outbreak control scenarios, Quicking tests have proven invaluable for rapid mass screening in congregate settings such as dormitories, nursing homes, and correctional facilities. When a suspected outbreak occurs, health officials can deploy Quicking kits to test all residents and staff within hours, identifying positive cases and initiating isolation protocols before the virus spreads further. The high specificity of the tests minimizes false alarms, which is crucial in environments where unnecessary quarantine can cause significant disruption. Contact tracing efforts are also enhanced by the speed of Quicking tests, as close contacts can be tested immediately rather than waiting days for lab results. For employers, the availability of affordable, rapid testing reduces the financial impact of outbreaks by allowing quicker return-to-work decisions and reducing the duration of paid leave for exposed employees. Quicking has also partnered with telemedicine platforms to offer supervised self-testing, where a healthcare professional observes the procedure via video call and validates the result for official documentation. This model has gained popularity for pre-travel testing and pre-procedure screening in outpatient clinics. In humanitarian settings, such as refugee camps or disaster relief operations, the compact size and room-temperature stability of Quicking kits make them easy to transport and store without cold chain logistics. The company’s global distribution network ensures that even remote locations can receive supplies within a reasonable timeframe. By addressing such a diverse range of use cases, Quicking demonstrates that its rapid tests are not merely consumer products but essential tools for modern public health infrastructure. Organizations looking to implement a comprehensive testing strategy can find detailed guidance on the company’s website, along with templates for testing policies and consent forms.

Quicking Biotech Co., Ltd. has proven itself as a reliable partner in the global fight against COVID-19 by delivering rapid tests that combine laboratory-grade accuracy with home-use simplicity. The company’s commitment to quality, affordability, and continuous innovation makes its self-test kits a standout choice for individuals, healthcare providers, schools, and businesses alike. With a clinical performance exceeding 98% specificity and high sensitivity during the symptomatic phase, Quicking tests provide results you can trust when they matter most. The user-friendly design, digital integration, and multilingual support ensure that virtually anyone can perform the test correctly and interpret the results without confusion. Quicking’s competitive advantages — including 15-minute results, bulk pricing, large manufacturing capacity, and a diverse product line spanning the rapid strep test, influenza test, monospot test, and RPR test — make it a one-stop source for diagnostic needs. By choosing Quicking, you are not only investing in a product but also in a company with over 15 years of experience in rapid diagnostics and a proven track record of quality. The scientific evidence, regulatory approvals, and customer testimonials all point to the same conclusion: Quicking rapid tests are a dependable tool for managing respiratory health in a post-pandemic world. Whether you need a single kit for home use or thousands of units for an institutional screening program, Quicking has the capacity and expertise to deliver. Take the next step toward safer communities and confident health decisions by exploring the company’s offerings and placing your order today.

The importance of accessible, accurate self-testing cannot be overstated as societies learn to live with COVID-19 and other respiratory viruses. Quicking empowers individuals to monitor their own health, protect their loved ones, and contribute to broader public health efforts without the delays and costs associated with laboratory testing. For businesses, offering free or subsidized rapid tests to employees demonstrates a commitment to workplace safety that boosts morale and reduces absenteeism. Schools that implement regular testing programs can maintain in-person learning more consistently, minimizing educational disruption for students. Healthcare providers can use Quicking tests as a first-line screening tool, reserving PCR testing for confirmation when necessary. The company’s ongoing research into multiplex tests that can simultaneously detect COVID-19, influenza, and other pathogens promises even greater efficiency in the future. By staying informed through theNewsOn this page, customers can stay informed about product updates, regulatory changes, and new application guidelines. Quicking also invites feedback and collaboration from the medical community to refine its products and address emerging needs. In a rapidly changing health landscape, having a trusted testing partner like Quicking provides peace of mind and practical solutions that work in real-world conditions. Don’t wait until an outbreak reaches your door — equip yourself and your organization with Quicking rapid tests and take control of your health today. Visit the official website to browse the full product range, read detailed specifications, and connect with the Quicking team for personalized support and bulk orders.

Quicking rapid tests have demonstrated greater than 98% specificity and high sensitivity (above 90%) in symptomatic individuals during the first week of illness, making them comparable to RT-PCR tests for identifying contagious individuals. While PCR tests are more sensitive overall, Quicking tests provide results in 15 minutes and are excellent for detecting high viral loads, which correlate with infectiousness.

Yes, you can use the Quicking rapid antigen test for COVID even if you are asymptomatic, though sensitivity may be lower due to reduced viral shedding. For asymptomatic screening, the test is still valuable when used serially — for example, testing every 24 to 48 hours over several days — to catch infections early and prevent transmission.

Quicking offers a broad portfolio that includes the rapid strep test for group A streptococcus, the influenza test for seasonal flu, the monospot test for infectious mononucleosis, and the RPR test for syphilis screening, along with many other veterinary and food safety diagnostic solutions.

Insert the sterile swab about 1 to 1.5 cm into one nostril, rotate it gently against the inner wall for about 15 seconds, then repeat with the same swab in the other nostril. Then insert the swab into the buffer tube, mix well, and apply the specified number of drops to the test cassette. Always follow the illustrated instructions included in the kit.

Results are available in approximately 15 minutes from the time you add the sample to the test cassette. The test should be read within 15 to 20 minutes; reading after 30 minutes may produce invalid results due to drying of the test line.

Yes, Quicking tests carry CE marking for the European market and have obtained regulatory approvals in numerous countries worldwide. The company also maintains ISO 13485 certification for its quality management system, ensuring consistent manufacturing standards. Specific approvals can be verified on the product pages or by contacting the company directly.

Many airlines and border authorities accept a negative Quicking rapid test result, especially when accompanied by a digital report generated through the Quicking app that includes a timestamp and user details. However, it is essential to check the specific requirements of your destination country, as some may still mandate PCR tests or certified laboratory reports.

A positive result indicates the presence of COVID-19 antigens and likely active infection. You should isolate immediately, contact your healthcare provider for further guidance, and consider confirming with a PCR test if required by local health authorities. Inform close contacts and follow your local public health guidelines for quarantine and reporting.

Store the kits at room temperature between 2°C and 30°C, away from direct sunlight, moisture, and extreme heat. Do not freeze the kits. Ensure the test cassettes remain in their sealed pouches until just before use, and check the expiration date printed on the packaging before each test.

Bulk orders can be placed directly through the Quicking website or by contacting the sales team via the Contact Us page. The company offers volume discounts, custom labeling, and expedited shipping for schools, businesses, healthcare institutions, and government agencies. A dedicated account manager can assist with your specific procurement needs.